å»è¬åå ¬è¡šãããæŽå¯
å€åœ¢æ§èé¢ç¯çåžå Žãè¬å€ã¿ã€ãå¥ïŒãã¢ã«ãã³é žãéã¹ããã€ãæ§æççè¬ïŒNSAIDïŒãé®çè¬ãã³ã«ãã³ã¹ããã€ãããã®ä»ïŒãæäžçµè·¯å¥ïŒçµå£ãéçµå£ããã®ä»ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«ïŒ... ãã£ãšèŠã
ã¢ãŒã©ã€ã³é žåžå ŽèŠæš¡ã¯ã2025幎ã®210.3çŸäžç±³ãã«ãã2032幎ã«ã¯358.1çŸäžç±³ãã«ã«éãããšäºæž¬ãããäºæž¬æéäžã®CAGRã¯7.9%ã§ãããã¢ãŒã©ã€ã³é žã¯ãæççäœçšãšæèäœçšãæã€å€©ç¶ç±æ¥ã®é žã§ããããã®é žã¯ãã³ã¡ãåè§£äœçšãè§è³ªæº¶è§£äœçšãæé žåäœçšããããããé ããã«ãã³ãªã©ã®ç®èçŸæ£ã®æ²»çã«äœ¿çšããããã¢ã±ã¢è£œåã«ããèŠããããã¢ãŒã©ã€ã³é žåžå Žã®å°åå¥ã€ã³ãµã€ãïŒ åç±³ã¯ã¢ãŒã©ã€ã³é žã®æå€§åžå Žã§ããã2025幎ã«ã¯38.7%ã®åžå Žã·ã§ã¢ãå ããç±³åœã¯å€§æäŒæ¥ã®ååšã«ããäºæž¬æéäžã®åžå Žæé·ã«å€§ããè²¢ç®ããŠãããåå°åã®æé·ãçœåŒããŠããã®ã¯ãæ¥çŒãæ¢ãå€ã®äœ¿çšæ¡å€§ãåç²§åæ¥... ãã£ãšèŠã
Pelargonic é žåžå Žã¯ USD 224.7 ã§è©äŸ¡ããããšæšå®ãããŸã 2025幎ã®Mnã¯USD 353.8ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ6.7%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºãã°ããŒãã«ãã©ãŒã®ãªã³é žåžå Ž - ã³ãããŠã€ã«ã¹ã®åœ±é¿(COVID-19)ãã³ãããã¯COVID-19 ã¯ãäžçç㪠pelargonic é žåžå Žã«å€§ããªåœ±é¿ãäžããŸããã äžåœãç±³åœãã€ã¿ãªã¢ãã€ã³ããå«ãäž»èŠãªåœã暪æããããã¯ããŠã³ã®åœ±é¿ã¯ãäžçåå°ã®ãµãã©ã€ãã§ãŒã³ã«æ··ä¹±ããããããŸããã ããã«ãã³ãããŠã€ã«ã¹ã®ç Žå£ã®åœ±é¿ãã³ã³ãããŒã«ããããã«ãããŸããŸãªåœ... ãã£ãšèŠã
Systemic Lupus Erythematosus(SLE)ã¯ãæ ¢æ§èªå·±å ç«é害ã§ãã äœã®çްèãéèŠãªèåšãæ»æããæäœã®éå°ãªçç£ã«ãã£ãŠç¹åŸŽä»ããããŸãã ç æ°ã«é¢é£ããããŸããŸãªçç¶ã«ã¯ãé¢ç¯ã®çã¿ãè «ããé¡ã®çºç¹(ãã¿ãã©ã€çºç¹)ããã³ä»ã®äœé åãé床ã®ç²åŽãæ¯æå€±ãè²§è¡ãããã³Raynaudã®çŸè±¡ãªã©ãå«ãŸããŸãã SLEã¯ãå¿èãè èãèºãè¡åã®å€åãªã©ã®éèŠãªäœåšå®ã«ã圱é¿ãåãŒãå¯èœæ§ããããŸãã ç æ°ã®æ£ç¢ºãªåå ã¯äžæã§ãããéºäŒçããã³ç°å¢çèŠå ã¯SLEã«ã€ãªããå¯èœæ§ããããŸãã SLEã«ã¯çŽæ¥æ²»çã¯ãããŸããããçç¶ã®æ²»çã¯ãç æ°ã«é¢é£ããçç¶ãäœäžãŸãã¯æé€ã... ãã£ãšèŠã
Tinnitusã¯ãå€éšãœãŒã¹ããæ¥ãŠããªãè³ã«äžå®ã®é³ã§ãã é³ã®æ§è³ªã¯ããªã³ã°ãããºãããŒã¢ãªã³ã°ãã¯ãªãã¯ãããŸããŸãªåŒ·åºŠã§åœŒã®æãããšã®å¯èœæ§ããããŸãã Tinnitusã¯ç æ°ã§ã¯ãªãçç¶ã§ãã è³é³Žãã®æ£ç¢ºãªç çåŠã¯ãŸã äžæã§ãããè³é³Žãã®ããŸããŸãªåå ã¯ãéšåçãªèŽèŠåªå€±ã倧ããªéšé³ãè³é³Žãããã®è³é³Žãã®éå¡ã骚ç²é¬ç(äžè³éªšã®åºå®)ãé éšã®å·å®³ããã³èžè³ç¥çµãªã©ã®æå·ã§ãã Tinnitusã¯ç掻ã®è³ªã«åœ±é¿ãåãŒããã¹ãã¬ã¹ã鬱ç ãéäžåäžè¶³ã«ã€ãªããå¯èœæ§ããããŸãã è³é³Žãçã¯æ²»ççæ³ãæã£ãŠããŸããããã¢ã¡ãªã«ã®è³é³ŽãåäŒã«ãããšãè³é³Žãçã®æ³šæçãææ çãèªç¥ç圱é¿ã«å¯Ÿ... ãã£ãšèŠã
ã¢ã¢ãšãããã£ãã¯æšªã®èæ±åŽåŒ¯ç(ALS)ã¯ãã©ãŠã»ã²ãªã°ç ãšã¢ãŒã¿ãŒãã¥ãŒãã³ç (MND)ãšãåŒã°ããè³å ã®ç¥çµçްèã«åœ±é¿ãåãŒããèªçºçãªçèãå¶åŸ¡ããèé«ã«åœ±é¿ãäžããç¥çµç³»çŸæ£ã§ãã ç æ°ã¯èªç¶ã®äžã§é²æ©çã§ãããæéããããŠæªåããããšãæå³ããŸãã2016幎ãç±³åœã«ãããALSããã³ALSã®æ®åçã¯ã2012幎10äžäººããã4.7çäŸã§ããã å¹³åå€ã10äžäººããã5.0çäŸã«å¢å ããåç ç©¶ã«ãããšã2013幎ã«ALSãšèšºæããã15,908人ååŸã«å¢å ããŸããã ALSã®å¢å€§çã¯ãè¿ãå°æ¥ãã¢ããã£ãã¯ãªæšªæ§èæ±åŽåŒ¯ç(ALS)æ²»çåžå Žã®æé·ããµããŒããããšæåŸ ãããŠããŸããæ°èŠ... ãã£ãšèŠã
ã¢ã«ããã€ããŒç (AD)ã¯ãèšæ¶ãæèãèšèªãè¡åã«åœ±é¿ãäžããèªç¥çã®äžçš®ã§ãã ã¢ã«ããã€ããŒç ã®å¹Žéœ¢ãé«éœ¢åã«èŠãã人ãå¢ãã65æ³ä»¥äžã¯ããã®é害ã®é²è¡ã«å€§ããªå±éºå åã§ãã 軜床ã®çç¶ã§å§ãŸããé床ã®è³æå·ã§çµãããšãå人ãäŒè©±ãéã¶èœåã倱ããç°å¢ã«åå¿ããã ã¢ã«ããã€ããŒåäŒã«ãããšã2017幎ãã¢ã«ããã€ããŒã®èªç¥çã«èŠããã§ãã5å以äžã®ã¢ã¡ãªã«äººãããŸãã æšå® 5.3 äžäººã¯65æ³ä»¥äžã20äžäººã®å人ã65æ³æªæºã§ãã¢ã«ããã€ããŒã®çºççã¯65æ³ä»¥äžã§ãã ã¢ã«ããã€ããŒã®èªç¥ããã³è¡åçç¶ã¯ãéè¬ç©æ²»çããã³å¯ŸçããŒã¹ã®è¬ã䜿çšããŠæ²»çããããšãã§ããŸãã ããããã¢... ãã£ãšèŠã
åç±³çç©åäžãã«ã¢ã³åžå Žã補åã¿ã€ãå¥ïŒãšã¹ããã²ã³ãããã²ã¹ããã³ããã¹ãã¹ããã³ãªã©ïŒãå€åœ¢å¥ïŒé å€ããã³ã«ãã»ã«ãã¯ãªãŒã ããã³ãžã§ã«ã泚å°å€ããããããã³ã€ã³ãã©ã³ããªã©ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãå°éã¯ãªããã¯ãããŒã ã±ã¢æœèšãªã©ïŒ... ãã£ãšèŠã
ãšãŒããããã¢ã»ã¢ã³ãäžæ±ããã³ã¢ããªã«ã®æ é€è£å©é£ååžå Žã補åã¿ã€ãå¥ïŒãã«ããã¿ãã³ãã¢ã·ã¥ã¯ã¬ã³ãããã³ãããã·å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ããããã·å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ããããŠçš®åãšãã¹å ¥ããã«ãããã©ã«ããã«ããã¿ãã³ãã€ãã§ãŠèãšãã¹å ¥ããã«ãããã©ã«ããããŠçš®åãšãã¹ããªã¿ããã³ãžã³ïŒã³ãªã³ããã«ããã¿ãã³ãã¢ãªã³ã¬å ¥ããã«ãããã©ã«ãããã³ ãã®ä»ïŒãçšéå¥ïŒæ§ã®å¥åº·ãå°å ã®å¥åº·ã女æ§ã®å¥åº·/婊人ç§ïŒã補å€å¥ïŒã«ãã»ã«ãé å€ãç²æ«ïŒãæµéãã£ãã«å¥ïŒåžå£²æ¥è ãšé»ååååŒïŒ... ãã£ãšèŠã
HIV-associated lipodystrophyå¥ålipodystrophyã¯HIVææããæ£è ã§èµ·ããã·ã³ãããŒã ã§ãã ããã¯é¡ããã¿ããã¯ãè ããã³è¶³ããã®ç®äžèèªã®æå€±ã«ãã£ãŠç¹åŸŽä»ããããŸãã HIV-associated lipodystrophy ã®æ£ç¢ºãªåå ã¯ååã«å®¹èªãããŠããŸããããæã¬ãããŠã€ã«ã¹è¬äžã«ããHIVæææ£è ã§èµ·ããããã€ãã®ç ç©¶ã®èšŒæ ã 2014幎ã«åœç«ç ç©¶éçºæ³äººãã€ãªãã¯ãããžãŒæ å ±ã»ã³ã¿ãŒ(NCBI)ã«æ²èŒãããèšäºã«ãããšãHIVã«ææãã人ã ã®lipodystrophyã®èå»¶ã¯10%ãš80%ã®éã§å€åããŸããHIVã®æ®åçã¯ãHIV-as... ãã£ãšèŠã
骚ã®ã»ã¡ã³ãã¯éªšãžã®æ¥åç®æã®æ³šå ¥ã®åºå®ã®ããã«äœ¿çšãããææã§ãã ããªã¡ãã«ã¡ã¿ã¯ãªã¬ãŒã(PMMA)ãŸãã¯å ±éåäœãæ§æããããªããŒããŒã¹ã®ææã§ããååŠéªšã®ã»ã¡ã³ãã¯Plexiglasã§ãã æŽåœ¢å€ç§äžã®ææã¯ãæçç©è³ªã®éªšã®ã»ã¡ã³ãã®äœ¿çšãäžå¯æ¬ ã§ããäž»èŠãªæžå¿µã§ãã é³é ææã¯å£ãããããŸãã¯å·ã€ããããéªšãæ¯ããã®ã«äœ¿çšãããŠããŸãã ãããã®ææã¯ãå£ãã骚ã®åšãã«æ¯æçãªã©ãããå 垯ãšããŠæ©èœããŸãã é³é ææã¯ããŸããŸãªåœ¢ããã³ãµã€ãºã§å©çšã§ããŸãããæçç©è³ªã®éªšã®ã»ã¡ã³ãã§äœ¿çšãããé³é ææã®æãäžè¬çãªã¿ã€ãã¯ãã©ã¹ã¿ãŒããã³ã¬ã©ã¹ç¹ç¶ã§ãã ç§ãéè·¯äºæ ãã¹ããŒãå·å®³... ãã£ãšèŠã
ã¿ãŠãªã³åžå Žã補åã¿ã€ãå¥ïŒåæã¿ãŠãªã³ããã³å€©ç¶ã¿ãŠãªã³ããã³çç©ç±æ¥ã¿ãŠãªã³ïŒãã°ã¬ãŒãå¥ïŒé£åããã³é£²æã°ã¬ãŒããå»è¬åã°ã¬ãŒãã飌æã°ã¬ãŒããåç²§åã°ã¬ãŒããªã©ïŒãçšéå¥ïŒæ é€ããªã³ã¯ãæ é€è£å©é£åãåç©é£Œæããã³ãããããŒããå»è¬åãä¹³å çšãã«ã¯ãåç²§åããã³ããŒãœãã«ã±ã¢ãªã©ïŒãæµéãã£ãã«å¥ïŒB2BçŽæ¥è²©å£²ãæå販売æ¥è ããªã³ã©ã€ã³B2Bãã©ãããã©ãŒã ãããã³ ãã®ä»)ãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
ãªãã«ã€ã³ãããã¯çµç®åžåå補å€ã§ãç é¢ãå°å£²åºããªã³ã©ã€ã³è¬å±ã§è³Œå ¥ã§ãããçã¿æ¢ããšããŠæãäžè¬çã«åŠæ¹ãããããŸããç¥çµçŸæ£ã«é¢é£ããçã¿ã®æ²»çãé·æçãªçã¿ã®åé¡ã®ç·©åã垯ç¶ç±ç¹ã«ããçã¿ã®ç·©åã«ã䜿çšãããã äžçã®ãªãã«ã€ã³ãããåžå Žã¯ã2022幎ã«ã¯10å5,560 äž ç±³ãã«ãš æšå®ãããäºæž¬æéïŒ2022-2030幎ïŒã«ã¯ CAGR 7.8 %ã瀺ããšäºæ³ãããŠããã å³1.ãªãã«ã€ã³ãããã®äžçåžå Žãéé¡ããŒã¹ïŒçŸäžç±³ãã«ïŒãå°åå¥ã2022幎 ãžã§ããªãã¯ãªãã«ã€ã³ããã補åã®å°å ¥ããäºæž¬æéäžã®äžçãªãã«ã€ã³ãããåžå Žã®æé·ãä¿é²ãããšäºæ³ãããã ãªãã«... ãã£ãšèŠã
Trigeminalç¥çµç(TN)ãå¥åtic douloureuxã¯ã第5é è³ãŸãã¯äžè§ç¥çµã«åœ±é¿ãäžããæ ¢æ§çŒçé害ã§ãã ã©ã€ã ç ããµã«ã³ã€ããŒã·ã¹ãå€çºæ§ç¡¬åçãå«ãå šèº«çŸæ£ã«ããççç¶æ ãåŒãèµ·ãããŸãã ãŸããå šèº«ã®Lupus erythematosusããã³sclerodermaãå«ãã³ã©ãŒã²ã³ã®è¡ç®¡çŸæ£ãšã®é¢é£ä»ãããããŸãã ç¥çµå€ç§ä»å ¥ãèŠæ±ããããŸã§ãé€ããŠãæ¡ä»¶ã¯å€æ¥åºç€ã§åŠçãããŸãã ãã®ç®¡çã¯ãæ£è ã®äžè¬çãªç¶æ ãšå¹Žéœ¢ã«åºã¥ããŠãåå¥ã«ã«ã¹ã¿ãã€ãºããå¿ èŠããããŸãã ããããæ¡ä»¶ã®æ£ç¢ºãªåå ã¯äžæã§ããTrigeminalç¥çµçã®åŠçœ®ã®åžå Žã¯è¬ç©çæ³ããã³å€ç§ã«... ãã£ãšèŠã
çµå£ã¯ãæäžã®çµå£çµè·¯ä»¥å€ã®ã«ãŒããä»ããŠç®¡çãããçæ®äžèœã®æäžéã®åœ¢æ ã§ãã 圌ãã¯çŽæ¥ãã£ãã·ã¥ãè¡ç®¡ãšæ¥è§ŠããŠç®ããã³æå¹æåã®1ã€ä»¥äžã®å±€ã«æ³šå ¥ãããŸãã 倧ãã容ç©ã®parenteralã¯2ã€ã®ã¿ã€ãã§ããå°ãã容ç©ã®parenteralã¯å®¹ç©100 mlãããå°ãªãéã®åäžãå€éã®æºåã§ãã倧ãã容ç©ã®parenteralã«100 ml以äžã®å®¹ç©ããããŸãã 倧容éã®æ¬åŒ§ã¯ãéèå æäžã®ããã®è¢ãŸãã¯ããã«ã«å ¥ã£ãŠãããæ¶²äœ/é»è§£æ¶²ãã©ã³ã¹ã®è£æ£ã«äœ¿çšãããããã¹ãããŒã¹ãªã©ã®æ é€ãæäŸããŸããç·©åã±ã¢ã®å¿ èŠæ§ãå¢å ãã倧容é éçµå£åžå Žã®æé·ãä¿é²ããããã®ããå€ç§çåŠçœ®ã®å¿ èŠ... ãã£ãšèŠã
ç±³åœããã³ãšãŒãããã®èšåºæ é€åžå Žãæäžçµè·¯å¥ïŒçµå£ãçµè žãéçµå£ïŒãçšéå¥ïŒãããä»£è¬æ§çŸæ£ãèè žçŸæ£ãç¥çµçŸæ£ãªã©ïŒã幎霢局å¥ïŒæäººãå°å ãé«éœ¢è ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒ... ãã£ãšèŠã
Liposarcoma ã¯æããã蚺æãããã¿ã€ãã®è»çµç¹ã® sarcomas ã® 1 ã€ãæããŸãã èèªçްèããæ·±ãçµç¹ã«ç±æ¥ããããã®äžçš®ã§ãã äžæ¹ãéå岿§ãªããµã«ãã¯ããµã«ã³ãã®ãã¹ãŠã®çš®é¡ãšåååè£ãããµã«ãããçããæãäžè¬çãªãµãã¿ã€ãã§ãã çµé²ããããªããµã«ãã®è «çã¯ãå žåçã«ã¯ã暪ããã£ãåŸæ¹/è ¹è ã«ååšããã ãããã®è «çã®çºçã®çç±ã¯ãŸã äžæã§ãããéºäŒåå€ç°ã¯ããããã®è «çã®çºçå åã®1ã€ã§ãããšèããããŠããŸãã é€èããã³æšçå ç«çæ³ã®ãããªããŸããŸãªçæ³ã«ãã£ãŠè «çã®å®å šãªåé€ããã³åãå€ããå«ãdedifferentiated sarcomaã®ããã®æãäž... ãã£ãšèŠã
Measlesãmumpsãããã³ rubellaã¯ãææãã人ã®çã¿ãå³ã«ãã£ãŠéä¿¡ããããŠã€ã«ã¹ã«ãã£ãŠéåžžã«åŒãèµ·ãããã3ã€ã®äžè¬çãªäŒææ§ç©ºæ°åªä»çŸæ£ã§ãããåäŸã®éã§æ·±å»ãªå䜵çãæ»ã«ã€ãªããå¯èœæ§ããããŸãã ãããã®ç æ°ã®ã¯ã¯ãã³ã¯ãåçµããããŠã€ã«ã¹ã¯ã¯ãã³ãšããŠè²©å£²ãããŠããŸãã, åçµä¹Ÿç¥è£œå€ã§è£œé , 泚å°çšåžéã®ããã®æ°Žãšåæ§æãå¿ èŠãšãããš2ã€ã®åœ¢æ ã§å©çšå¯èœã§ã. äŸãã°å䟡ã ãã§ãªããçµã¿åããã¯ã¯ãã³. MMRã¯ã¯ãã³ã¯ã2ã€ä»¥äžã®ãŠã€ã«ã¹æ ªã®æ··åç©ã§æ§æãããŠããŸãã ãããã®ã¡ã¢ã¹ã¬ããã ãŒãããã³ã«ãã©ã¯ã¯ãã³ã¯ãå°å ã ãã§ãªã倧人ã«ãç®äžæ³šå°ã«ãã£ãŠæäž... ãã£ãšèŠã